At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
TR701 FAdrug
Likely dose
TR701 FA 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Jan 27, 2012·Updated Aug 29, 2018
In Brief
A Phase 2 clinical trial evaluating TR701 FA for Major Cutaneous Abscess and 2 related conditions. Completed, enrolled 200 participants across 10 sites.
Detailed Summary
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Cutaneous Abscess, Cellulitis, Erysipelas
CountriesUnited States
CollaboratorsBayer
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartFeb 2012
Primary CompletionAug 2012
TodayJul 2026
First PostedJan 27, 2012
Enrollment StartFeb 15, 2012
Primary CompletionAug 27, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.4 years ago
Interventions
TR701 FAdrug
1 tablet 200 mg once daily